Cargando…
miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4
Acquired resistance to chemotherapy is a major obstacle in breast cancer (BC) treatment. Accumulated evidence has uncovered that microRNAs (miRNAs) are vital regulators of chemoresistance in cancer. Growing studies reveal that miR-137 acts as a suppressor in tumor progression. However, it remains ob...
Autores principales: | Du, Feiya, Yu, Ling, Wu, Ying, Wang, Shuqian, Yao, Jia, Zheng, Xiaoxiao, Xie, Shangzhi, Zhang, Shufeng, Lu, Xuemei, Liu, Yu, Chen, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892819/ https://www.ncbi.nlm.nih.gov/pubmed/31801953 http://dx.doi.org/10.1038/s41419-019-2164-2 |
Ejemplares similares
-
DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition
por: Kang, Xing, et al.
Publicado: (2017) -
miR-137 Inhibition of the Invasion, Metastasis, and Epithelial-Mesenchymal Transition of Nasopharyngeal Cancer by Regulating KDM1A
por: Lu, Han-qiang, et al.
Publicado: (2021) -
LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021) -
Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement
por: Zuchegna, Candida, et al.
Publicado: (2020) -
Dusp6 Inhibits Epithelial-mesenchymal Transition in Endometrial Adenocarcinoma Via ERK Signaling Pathway
por: Fan, Ming-Jun, et al.
Publicado: (2019)